Impact of Renal Impairment on the Pharmacodynamic and Pharmacokinetic Profiles of Epaminurad, a Novel Uric Acid Transporter 1 Inhibitor
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70266 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Seo Yeong Park und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, ChungBuk National University College of Medicine, Cheongju-si, Republic of Korea. Hauptthemen laut MEDLINE: Renal Insufficiency, Uricosuric Agents, Organic Anion Transporters, Organic Cation Transport Proteins. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chungbuk National University, JW Pharmaceutical Corporation.
Abstract (Originalsprache)
Epaminurad, a novel uricosuric agent, exhibits potent inhibitory activity against the human uric acid transporter. This study aimed to investigate the effects of renal function and food intake on the pharmacokinetic, pharmacodynamic, and safety characteristics of 9 mg epaminurad. This study was designed as a phase 1, partially randomized, open‐label, oral administration, partial crossover trial. Participants were assigned to three groups based on renal function: normal (Group 1), moderate renal impairment classified as Stage 3a (Group 2) and Stage 3b (Group 3). Each group aimed to enroll 6–10 participants. Blood and urine samples were collected to evaluate the pharmacokinetics and pharmacodynamics of epaminurad. Safety assessments were also conducted throughout the study. A total of 27 participants completed the study, including 12 with normal renal function (Group 1) and 9 and 6 participants with moderate renal impairment (Groups 2 and 3), respectively. When a single 9 mg dose of epaminurad was administered under fasted conditions, the pharmacokinetic, pharmacodynamic, and safety profiles did not show clear differences among the renal function groups. Furthermore, no notable differences were observed in these profiles between the fasted and fed states. Patients with moderate renal impairment can receive (eGFR of 30–59 mL/min/1.73 m 2 ) 9 mg epaminurad without dose adjustment, and the drug may be administered regardless of food intake.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, ChungBuk National University College of Medicine, Cheongju-si, Republic of Korea.
- Department of Clinical Pharmacology and Therapeutics, ChungBuk National University Hospital, Cheongju-si, Republic of Korea.
- Department of Pharmacology, Ajou University School of Medicine, Suwon-si, Republic of Korea.
ORCID-Profile: Seo Yeong Park, Jun Gi Hwang, Sung Kweon Cho, Min Kyu Park
Förderung
- Chungbuk National University
- JW Pharmaceutical Corporation
Zitieren
APA
Park, S. Y., Hwang, J. G., Cho, S. K., & Park, M. K. (2025). Impact of Renal Impairment on the Pharmacodynamic and Pharmacokinetic Profiles of Epaminurad, a Novel Uric Acid Transporter 1 Inhibitor. Clinical and Translational Science. https://doi.org/10.1111/cts.70266
Vancouver
Park SY, Hwang JG, Cho SK, Park MK. Impact of Renal Impairment on the Pharmacodynamic and Pharmacokinetic Profiles of Epaminurad, a Novel Uric Acid Transporter 1 Inhibitor. Clinical and Translational Science. 2025. doi:10.1111/cts.70266
BibTeX
@article{Park2025,
author = {Park, Seo Yeong and Hwang, Jun Gi and Cho, Sung Kweon and Park, Min Kyu},
title = {Impact of Renal Impairment on the Pharmacodynamic and Pharmacokinetic Profiles of Epaminurad, a Novel Uric Acid Transporter 1 Inhibitor},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70266}
}
EUVIMED